argenx SE (ARGX) Discusses Positive Phase 3 ALKIVIA Trial Results for VYVGART Hytrulo in Autoimmune Myositis - Slideshow

🇺🇸 Seeking Alpha (US) — 2026-08-20

argenx SE announced positive Phase 3 trial results for VYVGART Hytrulo in treating autoimmune myositis. The clinical success is a significant milestone for the company's treatment prospects in autoimmune diseases.

Markets Deals Health argenx SE clinical trial VYVGART Hytrulo autoimmune myositis Phase 3 biopharma

Read original source →

Coal’s shrinking tonnes are travelling further
Splash247 Maritime — 2026-09-22
Alibaba deepens AI push with new chip and bigger model
The Japan Times — 2026-09-22
Major milestone for energy exploration: ONGC strikes gas 43 km off Odisha coast
The Times of India — 2026-09-22
(LEAD) Seoul stocks edge up on chip gains amid renewed AI optimism; Korean won up
Yonhap News — 2026-09-22
Hapag-Lloyd introduces US$155/TEU Panama Canal charge
Container News — 2026-09-22
'Soltamos a besta': como o mundo se dividiu sobre até onde deixar a IA avançar
Globo — 2026-09-22

argenx SE (ARGX) Discusses Positive Phase 3 ALKIVIA Trial Results for VYVGART Hytrulo in Autoimmune Myositis - Slideshow

AI Summary

Related Articles

Coal’s shrinking tonnes are travelling further

Alibaba deepens AI push with new chip and bigger model

Major milestone for energy exploration: ONGC strikes gas 43 km off Odisha coast

(LEAD) Seoul stocks edge up on chip gains amid renewed AI optimism; Korean won up

Hapag-Lloyd introduces US$155/TEU Panama Canal charge

'Soltamos a besta': como o mundo se dividiu sobre até onde deixar a IA avançar